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Abstract 
Background: Type 1 diabetes (T1D) is characterised by loss of functional beta-cell mass necessitating insulin 
treatment. We hypothesise that combining low-grade and transient immune-modulation with a therapy to improve beta-
cell function could enable beta-cell survival with a lower risk of the complications associated with traditional immuno-
modulation. 
Methods: 308 adults recently diagnosed with T1D and residual C-peptide secretion were randomly assigned 1:1:1:1 to 
treatment in a double-blind, double-dummy manner with either anti-interleukin (IL)-21 plus liraglutide, anti-IL-21, 
liraglutide or placebo, all as adjunct to insulin. The trial comprised a 54-week treatment period followed by a 26-week 
observation period. For the primary endpoint (ratio of baseline versus week 54 meal-stimulated C-peptide secretion), 
there was 80% power to detect a decline of 2% with combination treatment compared to 35% with placebo. 
Findings: Stimulated C-peptide secretion decreased across groups; compared with placebo (-39%), the decrease from 
baseline at week 54 was significantly smaller (p=0·0017) with the combination (-10%) but not with anti-IL-21 (-25%) 
or liraglutide alone (-32%). Combination treatment (vs placebo) reduced insulin requirements (p=0.0006), glycated 
haemoglobin levels and the risk of hypoglycaemia. Benefits diminished upon treatment cessation. Changes in immune 
cell subsets across groups were transient and mild (<10% change over time). Generally, treatments were well-tolerated 
with no safety concerns. 
Interpretation: The novel combination of anti-IL-21 and liraglutide could preserve beta-cell function and improve 
glycaemic control in recently diagnosed T1D. The efficacy of this regimen appears comparable with that seen in other 
disease-modifying trials whilst providing a seemingly better side-effect profile.  
Funding: Novo Nordisk. 
  
Introduction 
Type 1 diabetes (T1D) is an autoimmune disease characterized by progressive loss of functional beta-cell mass. The 
incidence of T1D is increasing by 3% annually in high-income countries1; yet, the only currently available treatment for 
most people is life-long administration of exogenous insulin. 
Disease-modifying therapeutic interventions in T1D have focused on disease prevention in high-risk individuals and the 
preservation of residual beta-cell function soon after diagnosis.2-9 Both strategies have the potential to lead to better 
long-term glycaemic control, with lower rates of both hypoglycaemia and diabetes-related complications. Beta-cell 
function can be estimated based on C-peptide levels and patients with higher C-peptide levels have better glycaemic 
control and fewer and less pronounced long-term complications.10,11 Clinical trials have confirmed that the rate of post-
diagnosis decline of C-peptide levels can be attenuated; 2-4,8,9 in all trials, however, the benefit has lasted for the duration 
of treatment. While this indicates that prolonged treatment is necessary, it carries the advantage that, unless the 
intervention induces irreversible changes to the immune system, it may be possible to avoid that potential long-term 
benefits come at the expense of frequent side effects related to immune suppression such as infections12 including 
Epstein-Barr virus (EBV) reactivation13. 
 
We hypothesize that a disease-modifying therapy combining milder immune modulation with a beta-cell-focused agent 
to improve cell function as well as prevent beta-cell apoptosis under immune stress14 could ensure beta-cell survival 
with a lower risk of complications compared with traditional immunomodulation in newly diagnosed T1D. 
 
Anti-interleukin (IL)-21 is a promising candidate for immunotherapy in T1D because the IL-21 pathway has been 
linked to diabetes progression both in animal models15,16 and humans17,18, putatively owing to the central role of the 
cytokine in promoting the trafficking of CD8+ lymphocytes from the lymph nodes and/or exocrine pancreas to the 
islets19. Further, non-clinical investigations found a minor impact of IL-21 blockade on the immune repertoire19. 
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) such as liraglutide have been proposed to relieve beta-cell stress 
and prevent apoptosis20, protect against cytokine-mediated inhibitory effects on glucose-stimulated insulin secretion14 
and ameliorate the proinsulin-to-insulin processing defects seen in T1D and type 2 diabetes.21 Moreover, GLP-1 RAs 
have proven benefits on glycaemic control, body weight and cardiovascular risk.22,23 Thus, pursuing the concept of a 
combination therapy integrating immuno-modulation and a component aimed at another mechanistically distinct 
target24,25, the combination of IL-21 blockade and a GLP-1 RA had shown promising results in a mouse-model26. 
 
To elucidate these aspects in the clinical setting, we investigated the disease-modifying potential of anti-IL-21 and 
liraglutide in combination and as monotherapies, all as adjuncts to insulin, in a placebo-controlled trial in adults recently 
diagnosed with T1D.  
Methods 
Trial design 
This was an 80-week (54-week treatment period followed by a 26-week off-drug observation period), randomized, 
parallel-group, placebo-controlled, double-dummy, double-blind, efficacy, safety and clinical proof-of-principle trial in 
adults with recently-diagnosed T1D and residual beta-cell function. The trial was carried out at 95 sites in 17 countries. 
The trial is registered with ClinicalTrials.gov (NCT02443155), was approved by Independent Ethics Committees and 
Institutional Review Boards at each participating country/site, and was undertaken in accordance with ICH Good 
Clinical Practice guidelines and the Declaration of Helsinki. Investigators, participants and sponsor (Novo Nordisk) 
personnel were blinded throughout the treatment period. After all participants had completed the treatment period, Novo 
Nordisk personnel became unblinded due to an internal analysis aimed to inform on the future clinical development 
programme. Data were collected by site investigators via electronic case report forms.  
 
Participants 
Eligible individuals had been diagnosed with T1D within 20 weeks before screening with a peak mixed-meal tolerance 
test (MMTT)-derived C-peptide level ≥0·2 nmol/L and with antibodies against glutamic acid decarboxylase (GAD), 
islet antigen[IA]-2 and/or zinc-transporter-8 (ZnT8). Individuals were not enrolled if their T1D was considered unstable 
(an episode of severe diabetic ketoacidosis within 2 weeks of enrolment) or if they were at risk of infectious or chronic 




At week 0 (baseline), participants were randomly assigned 1:1:1:1 to treatment with one of the following: combination 
of anti-IL-21 and liraglutide, anti-IL-21, liraglutide or placebo. Randomisation was stratified according to the peak 
MMTT-derived C-peptide level at baseline (≥0·2 nmol/L to ≤0·6 nmol/L or >0·6 nmol/L). Anti-IL-21 at a dose of 12 
mg/kg and placebo for anti-IL-21 were administered intravenously every 6 weeks during visits to the trial sites. 
Liraglutide and placebo for liraglutide were self-administered as once-daily subcutaneous injections; there were no 
indications that treatment non-compliance differed relevantly across groups. The liraglutide dose was escalated from 
0·6 mg to a target of 1·8 mg/day in steps of 0·6 mg every 2 weeks. In the case of intolerable AEs related to dose 
escalation, the dose could be reduced to 1·2 mg. 
 
Participants received treatment for 54 weeks and were subsequently observed for 26 weeks following treatment 
cessation. All participants were on a treat-to-target insulin regimen throughout the trial. Participants were withdrawn 
from the trial if treatment was discontinued. 
 
Outcomes 
The primary outcome evaluated the decline in C-peptide secretion from baseline to week 54 and was assessed as the 
MMTT-stimulated C-peptide area under the concentration-time curve (AUC) over a 4-hour period at week 54 relative 
to baseline (AUC0-4h,C-peptide,week 54/AUC0-4h, C-peptide, baseline). MMTTs were scheduled at baseline and at weeks 12, 24, 36, 
54, 65 and 80. Other key efficacy outcomes included change from baseline to weeks 54 and 80 in MMTT-derived C-
peptide and plasma glucose, insulin use, glucose metabolism (glycated haemoglobin and glucagon) and 
pharmacokinetics (PK). Auto-antibodies against insulin, GAD, ZnT8 and IA2 were evaluated at the start of the trial and 
monitored throughout using commercial RIA, EIA and ELISA assay kits. The frequency and phenotype of circulating 
immune cell subsets (B, T, natural killer, and myeloid cells) were measured using peripheral blood mononuclear cells 
and flow cytometry. 
 
Key safety outcomes evaluated through week 80 included numbers of treatment-emergent AE, diabetic ketoacidosis, 
and hyperglycaemic and hypoglycaemic episodes. ‘Severe’ hypoglycaemic episodes were defined according to the 
ADA classification27; ‘severe or blood-glucose-confirmed symptomatic’ episodes also included those that were 
symptomatic and associated with a plasma glucose value <3.1 mmol/l (56 mg/dl).  
 
Statistical analysis 
Sample size calculation 
The trial was powered for the combination treatment vs placebo comparison for the primary endpoint, for which the 
assumed ratio to baseline was 0·98 (-2%) and 0·65 (-35%) for the combination and placebo treatments, respectively, 
corresponding to an assumed treatment ratio of 1·50 (treatment effect of 33 %-points). The standard deviation on the 
log-transformed primary endpoint was assumed to be 0·5 for the combination treatment and 1·0 for placebo. With 60 
subjects completing the trial in each of these two groups, the power would be 80·4% to detect a statistically significant 
treatment ratio. To account for non-completers, 77 subjects were randomly assigned to each treatment. The sample size 
for the anti-IL-21 and liraglutide groups was set to 77 subjects.  
 
Primary endpoint  
AUC0-4h, C-peptide,t / AUC0-4h, C-peptide, baseline at available timepoints (t) from baseline (week 0) to end-of-treatment (week 
54) were log-transformed and analysed using a mixed model for repeated measurements combined for all four 
treatments and including all available assessments for subjects in the full analysis set with a least one available 
observation (intention-to-treat approach). Missing data were assumed to be missing at random. In the model, treatment, 
C-peptide stratum and sex were factors, and log(AUC0-4h, C-peptide, baseline) and age at baseline were covariates; further, the 
interaction between all variables and time was included as a fixed effect. Estimated geometric mean ratios to baseline 
(presented as %-changes) and treatment ratios with 95% confidence intervals were derived from the model. In a 




A model similar to the one used for the primary endpoint was applied in the analysis of the other efficacy 
endpoints. Changes from baseline in glycated haemoglobin and immune biomarkers were analysed on the 
original scale, and the change from baseline in total daily insulin dose (average of the doses reported on the 
three days prior to the trial-site visits) was analysed using a normal linear regression model with treatment, 
stratum and sex as factors, and the baseline value and age at baseline as covariates.  
 
The total number of treatment-emergent ‘severe or blood-glucose-confirmed symptomatic’ and nocturnal 
‘severe or blood glucose-confirmed symptomatic’ hypoglycaemic episodes were analysed using a negative 
binominal regression model with a log link function, with the logarithm of the exposure time as an offset. 
The model included treatment, C-peptide stratum and sex as factors, and age as a covariate. In a post-hoc 
analysis, the total number of treatment-emergent hyperglycaemic episodes (PG values >16·7 mmol/l (300 
mg/dl) were analysed using a similar negative binominal regression model. 
 
No multiplicity correction was applied in any of the analysis, which were all performed using SAS version 
9.4.  
Role of the funding source 
The trial was sponsored by Novo Nordisk who designed the trial, monitored trial sites, and collected, analysed and 
interpreted the data. Medical writing and editorial support was funded by Novo Nordisk. The trial did not have a data 
monitoring committee. All authors had access to trial data upon request. The manuscript was drafted by the 
corresponding author under the guidance of all authors. The authors assume responsibility for the accuracy and 
completeness of the manuscript and the decision to submit it for publication.  
Results 
Between November 2015 through February 2019, 553 adults were assessed for eligibility. Of these, 308 participants 
were randomly assigned to treatment, which was received by 307 participants; one participant did not receive treatment 
and was excluded from the full analysis set. A total of 212 individuals screened for eligibility were not enrolled because 
they did not meet one or more eligibility criteria; the most common reasons for ineligibility were absence of islet-
specific autoantibodies (56 individuals), presence of certain laboratory abnormalities at screening (46 individuals), 
stimulated peak C-peptide ≥0.2 nmol/L (45 individuals) as well positive test result for tuberculosis (32 individuals) or 
hepatitis B (22 individuals). 
The trial profile is presented in Figure 1. The full analysis set and the safety analysis set each comprised the 307 
participants. The PK analysis set comprised 84 participants, which was considered sufficient to obtain an adequate 
precision for the PK outcomes. Across the four 77-participant groups, 8 to 12 participants did not complete the 
treatment period.  
In line with the randomised group assignment, participant characteristics (including age, gender, BMI, duration of 
diabetes, glycated haemoglobin levels and total daily insulin dose) were similar across treatment groups at baseline 
(Table 1). Across groups, the glycated haemoglobin level was 7·0% to 7·3% (53 to 56 mmol/mol) and most 
participants (58 to 65%) had a C-peptide level >0·6 mmol/L. 
 
With the combination therapy and with liraglutide alone, an initial increase in MMTT-derived stimulated C-peptide 
secretion (AUC0-4h) was observed; however, by end-of-treatment (week 54) and at the end of the off-drug observation 
period (week 80), the secretion had decreased in all groups (Figure 2a). The estimated decrease in C-peptide secretion 
from baseline to week 54 (primary endpoint) was statistically significantly smaller with the combination of anti-IL-21 
and liraglutide (10% decrease) than with placebo (39% decrease) with an estimated treatment ratio (ETR) of 1·48 
[1·16;1·89]95%CI (p=0·0017) (Figure 2b). At week 54, the MMTT-stimulated C-peptide secretion was around 48% 
greater with the combination treatment (AUC0-4h of 1·84 nmol×h/L) than with placebo (AUC0-4h of 1·24 nmol×h/L) 
(Figure 2a). The change from baseline to week 54 in MMTT-stimulated C-peptide secretion did not differ statistically 
significantly between the monotherapies (anti-IL-21 or liraglutide alone) and placebo (Figure 2b). Change from 
baseline in MMTT-stimulated C-peptide secretion were comparable whether based on 4-hour (Figure 2a-b) or 2-hour 
AUCs (Supplementary Table S1). Further, the findings were corroborated by stimulated plasma glucose values, which 
were reduced by the liraglutide-containing regimens (Supplementary Table S1) with a statistically significant 
difference at week 54 between the combination treatment and placebo (ETR for AUC0-4h of 0·88 [0·79;0·98]95%CI). 
Analysis of fasting C-peptide also supported the above results (Figure 3a-b): At week 54, fasting C-peptide levels 
largely had not changed in the combination therapy group; in contrast, the secretion had decreased by 36% in the 
placebo group; the change difference was statistically significant (p=0·0003; Figure 3b). 
 
A subgroup analysis demonstrated statistically significant (p=0·0214 for a test of interaction between treatment and C-
peptide stratum) differential treatment effects depending on the baseline C-peptide level (>0·2 nmol/L to ≤0·6 nmol/L 
or >0·6 nmol/L) (Supplementary Figure S1a-f) as exemplified by participants with a baseline value >0·6 nmol/L, in 
whom the change from baseline in stimulated C-peptide secretion at week 54 was similar between the combination 
therapy and liraglutide alone.  
 
With the combination of anti-IL-21 and liraglutide, the required total daily insulin dose decreased from baseline to week 
54 by 12% (0·04 U/kg body weight) (Supplementary Figure S2a-b); the decrease was statistically significant 
(p=0·0006) compared with the change with placebo (dose increase of 28% [0·09 U/kg]). Despite the greater insulin use 
in the placebo group in this treat-to-target trial (Supplementary Figure S2), the decrease in glycated haemoglobin at 
week 54 was greater with all active treatments (-0·50 %-points across groups) than with placebo (-0·10 %-points) 
(Figure 4a-b) although the treatment differences were not statistically significant. Fasting glucagon levels did not 
change relevantly in any of the groups. 
Body weight (protocol-defined safety endpoint) decreased from baseline to week 54 with the combination treatment and 
with liraglutide alone; compared with placebo, the decreases were statistically significant (Supplementary Table S4). 
 
At week 80 (i.e. after the 26-week off-treatment observation period), the changes from baseline in stimulated C-peptide 
secretion (Figure 2c, Supplementary Figure S1c and S1f, Supplementary Table S2), glycated haemoglobin (Figure 
4c) and total daily insulin dose (Supplementary Figure S2c) did not differ statistically significantly between the active 
treatments and placebo; the one notable exception was that the stimulated C-peptide secretion had decreased statistically 
significantly more with liraglutide alone than with placebo (-65% vs -49%; p=0·0065) (Figure 2c). 
 
There were no treatment-related differences in the number of patients with insulin autoantibodies or autoantibodies 
against GAD, ZnT8 and IA2 throughout the trial (data not shown). Overall, there were only minor and generally 
transient changes (<10%) in the frequency of conventional T cells (including regulatory), natural killer cells and 
myeloid cells with little impact on follicular T helper cells or B cells across timepoints and between treatment groups 
(Supplementary Figure S3); no safety issues related to these minor changes were identified. 
 
Treatment with liraglutide did not affect anti-IL-21 PK properties (Supplementary Table S3). 
 
All active treatments as well as placebo were generally safe and well-tolerated. Overall, AE and tolerability profiles 
observed for the active trial treatments (Table 2 and Supplementary Table S6) were consistent with previous reports 
on the use of anti-IL-21 treatment in humans and with the well-established profiles of GLP-1 RAs, including liraglutide 
in type 2 diabetes. Accordingly, the most frequently reported types of AE included gastrointestinal disorders, which are 
recognised as a known class effect with exogenous GLP-1 RAs. Apart from the gastrointestinal disorders, the most 
frequently reported AEs did not differ relevantly between the active treatments and placebo (Supplementary Figures 
S4 to S6) 
One participant died during the trial (while on treatment with liraglutide alone) in connection with the reported 3 AEs 
with fatal outcome (‘hypoglycaemic coma’, which after a marked drop in blood glucose in the early morning led to 
hospitalisation the same evening where ‘pneumonia’ and ‘brain oedema’ ensued); the 3 events were considered unlikely 
to be related to trial treatment and another potential causality was identified.  
AEs leading to participants withdrawing from the trial were infrequent across groups (2·7 to 3·7 and 1·8 events per 100 
years of exposure with the active treatments and placebo, respectively; Table 2). Of the 13 AEs leading to withdrawal, 
two were severe (‘hypoglycaemic coma’ and ‘brain oedema’ in the participant who died). Of the participants 
completing the treatment period, the large majority (72% to 82% for the active treatments and 88% for placebo) were 
dosed with liraglutide 1.8 mg; the remaining participants were on liraglutide 1.2 mg or had no information available. 
No safety concerns related to hypersensitivity reactions, injection/infusion site reactions, development of anti-drug 
antibodies, neoplasms, pancreatitis or thyroid disease were identified.  
At baseline across groups, 60·6% of the participants were positive for cytomegalovirus (CMV) immunoglobulin (Ig)G 
and 76·2% were positive for EBV-IgG. During the trial, there was no recurrence of CMV infections, whereas 5 EBV-
IgG-positive participants developed EBV-IgM antibodies (1 participants on combination treatment, 1 on anti-IL-21 
alone and 3 on placebo). All AEs related to positive EBV IgM samples were mild. 
A total of 3 participants (1 on combination treatment and 2 on anti-IL-21 alone) reported severe hypoglycaemic 
episodes during the treatment period; none were nocturnal (Table 2). In the treatment period, the rate of severe or blood 
glucose-confirmed symptomatic hypoglycaemic episodes was lower with the active trial treatments (418·9 to 525·3 
episodes per 100 years of exposure) than with placebo (675·2 episodes per 100 years of exposure) (Table 2); for 
liraglutide, the difference vs placebo was statistically significant with an ETR of 0·50 [0·30; 0·85]95%CI; 
Supplementary Figure S7 and Supplementary Table S5Error! Reference source not found.), whereas there were 
no differences upon trial treatment cessation in the observation period (Supplementary Table S5Error! Reference 
source not found.). 
During treatment, the rate of hyperglycaemic episodes was similar or lower with the active treatments compared with 
placebo (288·6 to 397·9 vs 390·6 episodes per 100 years of exposure, respectively); no events of diabetic ketoacidosis 
were observed (Table 2, Supplementary Table S5 and Supplementary Figure S8). In the observation period, the rate 
of hyperglycaemic episodes was significantly higher for the combination and liraglutide groups compared with placebo 
(Supplementary Tables S5 and S6Error! Reference source not found.).  
No unexpected or clinically important differences across groups were observed in clinical laboratory parameters or vital 
signs. As expected based on the well-known class effects of GLP-1 RAs, blood pressure, pulse rate and amylase and 
lipase levels changed during treatment with the combination treatment and liraglutide alone (Supplementary Table 
S4). 
Discussion 
The trial was successful in showing that one year of treatment with the combination of a monoclonal anti-IL-21 
antibody and the GLP-1 RA liraglutide was significantly better than placebo in preserving endogenous insulin secretion, 
measured by a 48% higher MMTT-stimulated C-peptide secretion after 54 weeks. The effect was accompanied by an 
almost complete maintenance of fasting baseline C-peptide secretion and a reduction in exogenous insulin need by 
almost one third. A trend showing a 34% reduction in hypoglycaemia was accompanied by reduced glycated 
haemoglobin levels, despite the treat-to-target trial design. Of note, the benefit of the combination therapy appeared 
more pronounced in the participants with a lower baseline C-peptide level (≤0·6 nmol/L) likely reflecting the beneficial 
effect of the anti-IL-21 component in preserving remaining beta-cell function. In those with a higher baseline C-peptide 
level reflecting more residual beta-cell function, the combination treatment and liraglutide alone were equally 
beneficial, suggesting that in this group of participants, the effect of liraglutide did not depend on the beta-cell 
preserving effect of anti-IL-21. Additional investigations are warranted to explore the patient subgroups likely to benefit 
the most from the combination.  
 
Importantly, no safety concerns were identified during the trial, with the treatments being well tolerated and with no 
indications of generalised immune suppression based on the assessed immune biomarkers, including multiple cell 
populations.  
 
The overall purpose of the combination treatment investigated in the present trial is to achieve safe preservation of beta-
cell function. It is well-recognized that even modest residual endogenous insulin secretion, as measured by low levels of 
C-peptide have important clinical benefits, including lower rates of hypoglycaemia and of diabetes-related 
complications, such as retinopathy.10,28-30 The benefits appear independent of, or at least additional to, improved 
glycated haemoglobin levels.2-4,31  
The efficacy of the combination therapy seen in the current trial appear at least on par with the best seen in other 
disease-modifying trials8,32 and also greater than each of the individual components (anti-IL-21 and liraglutide) given as 
monotherapy. Conversely, the observed benign safety profile of anti-IL-21 combined with liraglutide appears 
favourable compared with the safety profiles observed in previous attempts to preserve beta-cell function in recent-
onset T1D, where side effects appeared more severe and where long-term (months to years) changes to the immune 
system were seen, resulting in risk of, for example, reactivation of EBV infection12,13. 
 
Although the effect was less pronounced, anti-IL-21 alone also preserved C-peptide and was associated with similar 
trends in key glycaemic parameters (reduced glycated haemoglobin alongside less frequent severe or glucose-confirmed 
hypoglycaemic episodes). This supports a future role for anti-IL-21 treatment either as monotherapy or in combination 
with other agents in disease modulation in T1D.  
 
The identification of the exact mechanisms by which liraglutide plus anti-IL-21 leads to preservation of C-peptide 
secretion was not the purpose of the present trial and requires further study. However, evidence suggests that IL-21 
blockade reduces the pancreatic influx of new CD8+ effector T cells, thereby modulating the inflammatory process in 
the pancreas19. Similarly, liraglutide has the potential to relieve beta-cell stress and ameliorate the proinsulin-to-insulin 
processing defects seen in T1D.20,21 Thus, liraglutide might, in addition to evidently preserving glucose-induced insulin 
secretion under immune stress, also directly preserve beta-cell health. Of note, however, another GLP-1 RA, albiglutide, 
did not preserve β-cell function (vs placebo) during a recent 1-year trial in newly diagnosed T1D 33. To elucidate these 
important aspects, additional studies are needed, likely on organoids because no human in vivo beta-cell mass 
assessments are currently available. 
For the duration of the treatment period, the combination therapy was more efficacious than placebo in sustaining the 
endogenous C-peptide secretion capacity, with the observation for placebo likely reflecting the natural disease course. 
In contrast to most other comparable investigations, the present trial included an off-drug observation period of 26 
weeks immediately after the 54-week treatment period. This allowed for the observation that, upon cessation of 
treatment, the beneficial effects diminished rapidly as the ongoing autoimmune process presumably resumed its course. 
Arguably, this is a positive finding, considering that it indicates that the treatments did not induce permanent changes to 
the immune system as seen with other immuno-modulatory interventions. 
Interestingly, there appeared to be a more rapid decline in C-peptide secretion during the observation period (i.e. after 
treatment cessation) in the combination therapy and liraglutide-alone groups, which might reflect the observed increase 
in hyperglycaemia after cessation of liraglutide (with or without anti-IL-21). The hyperglycaemia may have been due to 
a delayed up-titration or otherwise sub-optimal titration of the insulin dose in these groups in particular. This notion is 
corroborated by the well-established marked glycaemic efficacy of GLP-1 RAs such as liraglutide that may had 
required tighter insulin titration than the one specified in the trial protocol or applied at the trial sites. Whatever the 
cause, the observed hyperglycaemia might have led to increased glucose toxicity towards the beta cell and in turn to the 
observed more rapid decrease in C-peptide secretion in the liraglutide-containing regimens. Moreover, further damage 
to the beta cell could also arise from liraglutide withdrawal via an increase in self-presentation of the beta-cell 
autoantigen pro-insulin. 
 
C-peptide and plasma glucose outcomes were assessed using 4-hour AUC values by default; 2-hour AUC values were 
also derived, and for the primary outcome (stimulated C-peptide secretion) the results and the statistical inferences were 
overall consistent across the two AUC approaches with the addition that anti-IL-21 alone was statistically significant 
better at preserving C-peptide secretion than placebo when evaluated using the 2-hour but not the 4-hour AUC. Of note, 
the 4-hour AUC was the default because evidence was available to suggest that Cmax for C-peptide is reached around 2-
hours after a meal.  
 
Whether the benefits of the combination therapy can be sustained beyond the 54 weeks studied in the present trial will 
require further evaluation. Future trials should also address the period following treatment withdrawal with a specific 
focus on glycaemia.  
 
Finally, the weight loss reduction seen with the liraglutide-containing regimens are in line with the licenced use of 
liraglutide in weight management and constitute an additional benefit of a T1D intervention, considering that T1D may 
be associated with excess body weight. 
 
In conclusion, treatment with the combination of anti-IL-21 and liraglutide for 54 weeks was well-tolerated and resulted 
in sustained endogenous insulin secretion in response to an MMTT and improved glucose metabolism compared with 
placebo. The results imply that the combination of anti-IL-21 and liraglutide has the potential to offer a novel and 
valuable disease-modifying therapy for patients recently diagnosed with T1D.   
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Figures and tables 
Figure 1 Trial profile 
 
Analyses of efficacy and biomarker endpoints were based on the full analysis set, which includes all participants randomly assigned to a treatment 
group. Only in exceptional cases were participants excluded from the full analysis set; in such cases, the reason for exclusion was justified and 
documented. For analyses based on the full analysis set, participants contributed according to the trial treatment assigned at randomisation. Analyses of 
the pharmacokinetic (PK) endpoints were based on the PK analysis set, which includes randomised participants with a full PK profile and with at least 
one valid PK measurement. Analyses of safety endpoints were based on the safety analysis set, which includes all participants who were exposed to trial 
treatment. For analyses based on the PK and safety analysis sets, participants contributed according to the trial treatment actually received. IL, 
interleukin; PK, pharmacokinetic. 
 
Figure 2: MMTT-stimulated C-peptide secretion 
 
 
Data are observed geometric means by week (Panel A) and estimated geometric mean changes from baseline 
at end-of-treatment (week 54, Panel B) and end-of-trial (week 80, Panel C). Number of participants (N) 
contributing to the observed means (Panel A) or the analysis (Panels B and C) are presented. Data were log-
transformed; in the statistical analysis, data were then analysed using a mixed model for repeated measures 
with treatment group, sex and C-peptide stratum as factors, and baseline value and age as covariates, as well 
as the interaction between all variables and time. Estimated changes from baseline calculated on the 
multiplicative scale as ratios to baseline are presented as %-changes from baseline; the estimated treatment 
contrasts and the associated 95% CI are presented as the ratio of the estimated ratios to baseline between 
active treatment and placebo. Participants with at least one post-baseline value contribute to the statistical 
analysis. *p<0.05 vs placebo. AUC, area under the time-concentration curve; CI, confidence interval; ETR, 




Figure 1. Fasting C-peptide secretion   
 
 
Data are observed geometric means by week (Panel A) and estimated geometric mean changes from baseline 
at end-of-treatment (week 54, Panel B) and end-of-trial (week 80, Panel C). Number of participants (N) 
contributing to the observed means (Panel A) or the analysis (Panels B and C) are presented. Data were log-
transformed; in the statistical analysis, data were then analysed using a mixed model for repeated measures 
with treatment group, sex and C-peptide stratum as factors, and baseline value and age as covariates, as well 
as the interaction between all variables and time. Estimated changes from baseline calculated on the 
multiplicative scale as ratios to baseline are presented as %-changes from baseline; the estimated treatment 
contrasts and the associated 95% CI are presented as the ratio of the estimated ratios to baseline between 
active treatment and placebo. Participants with at least one post-baseline value contribute to the statistical 
analysis. *p<0.05 vs placebo. CI, confidence interval; ETR, estimated treatment ratio; IL, interleukin. 
  
 
Figure 2: Glycated haemoglobin 
 
 
Data are observed means by week (Panel A) and estimated mean changes from baseline at end-of-treatment 
(week 54, Panel B) and end-of-trial (week 80, Panel C). Data were analysed using a mixed model for 
repeated measures with treatment group, sex and C-peptide stratum as factors, and baseline value and age as 
covariates. Participants with at least one post-baseline value contribute to the statistical analysis. 




Table 1: Demographics and baseline characteristics 
 Combination 
(FAS = 77) 
Anti-IL-21 
(FAS = 77) 
Liraglutide 
(FAS = 76) 
Placebo 
(FAS = 77) 
Age, years 28·0±7·5 28·6±7·9 28·0±7·1 29·0±7·0 
Females, N 21 (27·3) 32 (41·6) 25 (32·9) 28 (36·4) 
BMI, kg/m2 22·9±3·8 23·7±3·4 24·2±3·8 24·0±5·0 
Duration of type 1 diabetes, weeks 11·6±5·7 11·5±5·3 10·8±4·8 10·2±4·7 
Glycated haemoglobin, % 7·1±1·5 7·0±1·3 7·2±1·5 7·3±1·3 
Glycated haemoglobin, mmol/mol 54±16 53±14 55±16 56±14 
Baseline MMTT-derived peak C-peptide     
≤0·6 nmol/L, N 31 (40·3) 27 (35·1) 32 (42·1) 30 (39·0) 
>0·6 nmol/L, N 46 (59·7) 50 (64·9) 44 (57·9) 47 (61·0) 
Baseline mean total daily insulin dose 0·32±0·21 0·33±0·19 0·30±0·17 0·32±0·21 
Mean daily bolus insulin dose, U/kg 0·17±0·11 0·16±0·11 0·16±0·10 0·16±0·12 
Mean daily basal insulin dose, U/kg 0·19±0·12 0·19±0·11 0·16±0·09 0·19±0·11 
Number of severe hypoglycaemic episodes since diagnosis 
0 episodes, N 75 (97·4) 77 (100) 76 (100) 76 (98·7) 
1 episode, N 2 (2·6) 0 0 1 (1·3) 
Number of islet-specific auto-antibodies 
1 auto-antibody, N 24 (31.2) 20 (26.0) 22 (28.9) 28 (36.4) 
2 auto-antibodies, N 22 (28.6) 27 (35.1) 21 (27.6) 24 (31.2) 
3 auto-antibodies, N 31 (40.3) 30 (39.0) 33 (43.4) 25 (32.5) 
Data are means (±SD) or participant counts (proportion relative to the FAS) for participants in the full 
analysis set. Baseline is defined as the time of randomisation or latest information prior to this. BMI, body 
mass index; FAS, full analysis set; IL, interleukin; MMTT, mixed-meal tolerance test; N, number of 
subjects; SD, standard deviation. 
 
Table 2: Treatment-emergent adverse events and hypoglycaemic and hyperglycaemic episodes 
 Combination Anti-IL-21 Liraglutide Placebo 
 N % R N % R N % R N % R 
Safety analysis set 77   77   76   77   
Patient-years of exposure 75·85   75·04   75·17   74·51   
All adverse events 59 76·6 572 64 83·1 436 65 85·5 545 63 81·8 489 
Possibly or probably related to             
Anti-IL-21 25 32·5 88·3 20 26·0 72·0 22 28·9 125·0 24 31·2 87·2 
Liraglutide 37 48·1 176·5 24 31·2 72·0 50 65·8 208·8 27 35·1 108·7 
Serious AE 6 7·8 8 3 3·9 5 7 9·2 13 7 9·1 12 
AE leading to withdrawal 3 3·9 3·6 4 5·2 3·7 2 2·6 2·7 2 2·6 1·8 
Most frequently reported AE a             
Nasopharyngitis 18 23·4 35·6 23 29·9 57·3 22 28·9 54·5 22 28·6 47·0 
Nausea 19 24·7 43·5 6 7·8 12·0 41 53·9 81·1 9 11·7 17·4 
Vomiting 13 16·9 30·3 0 0·0 0·0 17 22·4 43·9 3 3·9 5·4 
Diarrhoea 12 15·6 21·1 8 10·4 18·7 13 17·1 26·6 8 10·4 12·1 
Headache 9 11·7 19·8 8 10·4 12·0 9 11·8 13·3 10 13·0 18·8 
Oropharyngeal pain 10 13·0 14·5 11 14·3 20·0 3 3·9 6·6 7 9·1 10·7 
Decreased appetite 14 18·2 19·8 2 2·6 2·7 11 14·5 17·3 1 1·3 1·3 
Hypoglycaemic episodes             
ADA classification 73 94·8 4419·0 73 94·8 4560·0 69 90·8 4287·2 73 94·8 4578·5 
Severe 1 1·3 1·3 2 2·6 2·7 0 0·0 0·0 0 0·0 0·0 
Severe or blood glucose-confirmed 
symptomatic b 
43 55·8 521·7 55 71·4 525·3 46 60·5 418·9 51 66·2 675·2 
Hyperglycaemic episodes c 32 41·6 397·9 31 40·3 341·3 29 38·2 288·6 36 46·8 390·6 
Diabetic ketoacidosis 0 0·0 0·0 0 0·0 0·0 0 0·0 0·0 0 0·0 0·0 
a Events with an overall rate (R) of ≥10 events per 100 participant-years of exposure. 
b ’Severe or blood glucose-confirmed symptomatic’ hypoglycaemic episodes are either severe according to the ADA classification27 or an episode 
confirmed by a plasma blood glucose <3.1 mmol/L (56 mg/dL) and with symptoms consistent with hypoglycaemia.  
c Hyperglycaemic episodes were defined as and confirmed by plasma glucose values >16.7 mmol/l (300 mg/dl). 
ADA, American Diabetes Association; AE, adverse event; IL, interleukin; N, number of participants with at least one event; %, proportion of 
participants with at least one event; R, events per 100 participant-years of exposure.  
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Supplementary Figure S1 Stimulated C-peptide secretion by baseline C-peptide stratum 
 
Treatment by stratum interaction p-value = 0.0214. Panels A-C: participants in the low baseline C-peptide 
stratum (0.2nmol/L ≤ MMTT-derived peak C-peptide ≤ 0.6nmol/L; N=120 (39.1%)). Panel D-F: participants  
in the high baseline C-peptide stratum (MMTT-derived peak C-peptide > 0.6nmol/L; N=187 (60.9%)). 
 
Number of participants (N) contributing to the observed means (Panels A and D) or the analysis (Panels B, 
C, E and F) are presented. Data were log-transformed; in the statistical analysis, data were then analysed 
using normal linear regression with treatment group, sex and C-peptide stratum as factors and baseline value 
and age as covariates. Participants with data for baseline and week 54/80 contributed to analysis. *p<0.05 vs 
placebo. CI, confidence interval; ; IL, interleukin.
 
Supplementary Figure S2 Total daily insulin dose 
 
 
Data are observed means by week (Panel A) and estimated mean changes from baseline at end-of-treatment 
(week 54, Panel B) and end-of-trial (week 80, Panel C). Number of participants (N) contributing to the 
observed means (Panel A) or the analysis (Panels B and C) are presented. Data were log-transformed; in the 
statistical analysis, data were then analysed using normal linear regression with treatment group, sex and C-
peptide stratum as factors and baseline value and age as covariates. Participants with data for baseline and 
week 54/80 contributed to analysis. *p<0.05 vs placebo. CI, confidence interval; ; IL, interleukin. 
 






Symbols are estimated changes from baseline (%) vs placebo at weeks 54 and 80 with 95% confidence 
intervals. Data were log-transformed; in the statistical analysis, data were then analysed using normal linear 
regression with treatment group, sex and C-peptide stratum as factors and baseline value and age as 
covariates. Participants with data for baseline and week 54/80 contributed to analysis. Cells populations were 
counted using flow cytometry. IL, interleukin. 
 
Supplementary Figure S4 Adverse events for the combination versus placebo in the treatment period 
 
Figure includes events reported for at least 5% of the participants in either treatment group. The rate ratios 
were estimated using a negative binomial regression with treatment, stratum and sex as factors and age as 
covariate.  
CI, confidence interval; N, number of participants; PYE, patient-years of exposure. 
 
 
Supplementary Figure S5 Adverse events for anti-IL-21 versus placebo in the treatment period 
 
Figure includes events reported for at least 5% of the participants in either treatment group. The rate ratios 
were estimated using a negative binomial regression with treatment, stratum and sex as factors and age as 
covariate.  
CI, confidence interval; IL, interleukin; N, number of participants; PYE, patient-years of exposure. 
 
 
Supplementary Figure S6 Adverse events for liraglutide versus placebo in the treatment period 
 
Figure includes events reported for at least 5% of the participants in either treatment group. The rate ratios 
were estimated using a negative binomial regression with treatment, stratum and sex as factors and age as 
covariate.  
CI, confidence interval; N, number of participants; PYE, patient-years of exposure. 
 
 
Supplementary Figure S7 Severe or blood glucose-confirmed symptomatic hypoglycaemia 
 
Severe or blood-glucose confirmed hypoglycaemia is defined as episodes that are severe according to the 
ADA classification or blood-glucose confirmed by a plasma glucose value <3.1 mmol/l (56 mg/dl) with 
symptoms consistent with hypoglycaemia. ADA, American Diabetes Association; IL, interleukin. 
 
Supplementary Figure S8 Hyperglycaemia  
 





Supplementary Table S1 Other supportive secondary efficacy endpoints – week 54 
Treatment group N Ratio to baseline ETR (vs placebo) 95% CI 
C-peptide AUC0-2h     
Anti-IL-21 + liraglutide 75 0·93 1·56 [1·23; 1·99] 
Anti-IL-21 75 0·79 1·32 [1·04; 1·68] 
Liraglutide 74 0·63 1·06 [0·83; 1·35] 
Placebo 73 0·60 - - 
Plasma glucose AUC0-4h     
Anti-IL-21 + liraglutide 75 0·96 0·88 [0·79; 0·98] 
Anti-IL-21 75 1·06 0·98 [0·88; 1·09] 
Liraglutide 74 1·00 0·92 [0·83; 1·02] 
Placebo 73 1·08 - - 
Plasma glucose AUC0-2h     
Anti-IL-21 + liraglutide 75 0·98 0·94 [0·86; 1·03] 
Anti-IL-21 75 1·05 1·00 [0·91; 1·10] 
Liraglutide 74 0·99 0·95 [0·86; 1·04] 
Placebo 73 1·04 - - 
Fasting plasma glucagon     
Anti-IL-21 + liraglutide 76 1·00 1·00 [0·91; 1·10] 
Anti-IL-21 76 0·96 0·96 [0·87; 1·06] 
Liraglutide 75 0·97 0·97 [0·88; 1·07] 
Placebo 75 1·00 - - 
AUC, area under the curve; CI, confidence interval; ETR, estimated treatment ratio; IL, interleukin; N: 
number of patients contributing to the analysis. 
  
 
Supplementary Table S2 Other supportive secondary efficacy endpoints - week 80 
Treatment group N Ratio to baseline ETR (vs placebo) 95% CI 
C-peptide AUC0-4h     
Anti-IL-21 + liraglutide 75 0·55 1·08 [0·82; 1·43] 
Anti-IL-21 75 0·57 1·11 [0·84; 1·46] 
Liraglutide 74 0·35 0·68 [0·52; 0·90] 
Placebo 73 0·51 - - 
C-peptide AUC0-2h     
Anti-IL-21 + liraglutide 75 0·58 1·25 [0·94; 1·67] 
Anti-IL-21 75 0·58 1·26 [0·95; 1·68] 
Liraglutide 74 0·35 0·75 [0·57; 1·00] 
Placebo 73 0·46 - - 
Plasma glucose AUC0-4h     
Anti-IL-21 + liraglutide 75 1·19 0·99 [0·89; 1·09] 
Anti-IL-21 75 1·09 0·91 [0·83; 1·01] 
Liraglutide 74 1·16 0·97 [0·87; 1·07] 
Placebo 73 1·20 - - 
Plasma glucose AUC0-2h     
Anti-IL-21 + liraglutide 75 1·16 1·02 [0·93; 1·11] 
Anti-IL-21 75 1·06 0·93 [0·85; 1·01] 
Liraglutide 74 1·10 0·96 [0·88; 1·04] 
Placebo 73 1·14 - - 
Fasting plasma glucagon     
Anti-IL-21 + liraglutide 76 0·89 0·96 [0·86; 1·07] 
Anti-IL-21 76 0·86 0·92 [0·82; 1·03] 
Liraglutide 75 0·96 1·03 [0·93; 1·15] 
Placebo 75 0·93 - - 
AUC, area under the curve; CI, confidence interval; ETR: estimated treatment ratio; IL, interleukin, N, 
number of patients contributing to the analysis.  
 
Supplementary Table S3 Pharmacokinetic properties of anti-IL-21 




Endpoint (unit) Geometric mean (CV%) 
AUCτ, anti-IL-21, area under the anti-IL-21 time-
concentration curve over a dosing interval at steady state 
(day*ug/mL) 
3969 (17·9) 4115 (23·1) 
Terminal t½, half-life after last dose of anti-IL-21 (days) 22·3 (17·9) 22·2 (16·5) 
Vss, anti-IL-21, the apparent volume of distribution of anti-IL-
21 at steady-state (mL/kg) 
83·7 (23·1) 79·3 (17·6) 
CLss, anti-IL-21, clearance of anti-IL-21 at steady-state 
([mL/day]/kg) 
3·02 (17·9) 2·92 (23·1) 
MRT, anti-IL-21, the mean residence time of anti-IL-21 (days) 27·7 (24·5) 27·2 (22·6) 
RA,AUC, anti-IL-21, accumulation ratio of anti-IL-21 defined as 
AUC48-54 weeks/AUC0-6 weeks (ratio) 
1·24 (17·8) 1·26 (17·4) 
Anti-IL-21 concentration prior to dosing of anti-IL-21 at 
steady-state (ug/L) 
34·7 (42·3) 36·7 (36·8) 
Anti-IL-21 concentration 1 h after dosing of anti-IL-21 at 
steady state (ug/L) 
298·6 (16·8) 282·6 (56·4) 




Supplementary Table S4 Vital signs and amylase and lipase measurements at weeks 54 and 80 
Treatment group N Change from baseline ETD (vs placebo) 95% CI 
Systolic blood pressure (mmHg), week 54 
Anti-IL-21 + liraglutide 76 -0 -4 [-7;-0] 
Anti-IL-21 77 2 -1 [-4;2] 
Liraglutide 75 2 -1 [-5;2] 
Placebo 76 3 - - 
Diastolic blood pressure (mmHg), week 54 
Anti-IL-21 + liraglutide 76 0 -0 [-3;2] 
Anti-IL-21 77 2 2 [-1;4] 
Liraglutide 75 1 1 [-2;3] 
Placebo 76 1 - - 
Pulse rate (beats per minute), week 54     
Anti-IL-21 + liraglutide 76 -1 -1 [-4;2] 
Anti-IL-21 77 -0 -1 [-4;2] 
Liraglutide 75 2 1 [-2;4] 
Placebo 76 1 - - 
Body weight (kg), week 54     
Anti-IL-21 + liraglutide 76 -1·8 -3·0 [-4·6; -1·4] 
Anti-IL-21 77 1·3 0·1 [-1·5;1·7] 
Liraglutide 75 -2·6 -3·8 [-5·4; -2·2] 
Placebo 76 1·2 - - 
Body weight (kg), week 80     
Anti-IL-21 + liraglutide 76 1·8 -1·0 [-2·7 ; 0·7] 
Anti-IL-21 77 1·8 -1·0 [-2·7 ; 0·7] 
Liraglutide 75 0·3 -2·5 [-4·2 ; -0·8] 
Placebo 76 2·8 - - 
  Ratio to baseline ETR (vs placebo) 95% CI 
Amylase (U/L), week 54     
Anti-IL-21 + liraglutide 76 1·04 1·01 [0·94;1·09] 
Anti-IL-21 77 0·98 0·96 [0·89;1·03] 
Liraglutide 75 1·04 1·02 [0·95;1·09] 
Placebo 76 1·03 -  
Lipase (U/L), week 54     
Anti-IL-21 + liraglutide 76 1·06 1·08 [0·97;1·20] 
Anti-IL-21 77 0·92 0·95 [0·86;1·06] 
Liraglutide 75 1·02 1·05 [0·95;1·16] 
Placebo 76 0·98 -  
N, number of participants contributing to the analysis. ETD, estimated treatment difference; ETR, estimated 
treatment ratio; IL, interleukin. 
  
 
Supplementary Table S5 Analysis of hypoglycaemic and hyperglycaemic endpoints 





Treatment period    
Severe or blood glucose-confirmed symptomatic hypoglycaemia 
Anti-IL-21 + liraglutide 77 468·6 0·66 [0·39; 1·12] 
Anti-IL-21 77 490·0 0·69 [0·41; 1·16] 
Liraglutide 76 355·7 0·50 [0·30; 0·85] 
Placebo 77 708·3 - - 
Nocturnal severe or blood glucose-confirmed symptomatic hypoglycaemia 
Anti-IL-21 + liraglutide 77 54·9 0·89 [0·38; 2·12] 
Anti-IL-21 77 43·3 0·70 [0·29; 1·71] 
Liraglutide 76 42·5 0·69 [0·29; 1·63] 
Placebo 77 61·5 - - 
Hyperglycaemia     
Anti-IL-21 + liraglutide 77 481·8 1·27 [0·59; 2·73] 
Anti-IL-21 77 278·4 0·73 [0·34; 1·57] 
Liraglutide 76 192·0 0·51 [0·23; 1·12] 
Placebo 77 379·3 - - 
Observation period   
Severe or blood glucose-confirmed symptomatic hypoglycaemia 
Anti-IL-21 + liraglutide 77 558·1 0·80 [0·36; 1·77] 
Anti-IL-21 77 355·9 0·51 [0·23; 1·13] 
Liraglutide 76 575·3 0·83 [0·39; 1·77] 
Placebo 77 695·4 - - 
Nocturnal severe or blood glucose-confirmed symptomatic hypoglycaemia 
Anti-IL-21 + liraglutide 77 117·8 1·74 [0·60; 5·01] 
Anti-IL-21 77 25·4 0·37 [0·11; 1·24] 
Liraglutide 76 75·6 1·12 [0·39; 3·16] 
Placebo 77 67·7 - - 
Hyperglycaemia     
Anti-IL-21 + liraglutide 77 866·0 2·91 [1·18; 7·2] 
Anti-IL-21 77 186·7 0·63 [0·25; 1·59] 
Liraglutide 76 801·6 2·69 [1·10; 6·60] 
Placebo 76 297·5 - - 
Nocturnal hypoglycaemic episodes: episodes occurring between 00:01 and 05:59 both inclusive. Estimated 
rates are weighed according to the distribution in the data. CI, confidence interval; IL, interleukin; N, number 
of participants contributing to analysis. 
 
Supplementary Table S6 Adverse events in the observation period 
 Combination Anti-IL-21 Liraglutide Placebo 
 N % R N % R N % R N % R 
Participants (N) 77   77   76   77   
Participant-years of observation 34·88   33·07   35·04   33·57   
All adverse events 34 44·2 201 36 46·8 221 31 40·8 223 31 40·3 259 
Possibly or probably related to             
Anti-IL-21 1 1·3 2·9 2 2·6 12·1 4 5·3 17·1 3 3·9 8·9 
Liraglutide 1 1·3 2·9 2 2·6 12·1 3 3·9 14·3 2 2·6 6·0 
Serious adverse events 4 5·2 11 2 2·6 6 4 5·3 14 5 6·5 36 
Most frequently reported adverse events a             
Nasopharyngitis 7 9·1 22·9 14 18·2 60·4 9 11·8 25·7 8 10·4 29·8 
Headache 4 5·2 20·1 3 3·9 9·1 1 1·3 2·9 2 2·6 8·9 
Hypoglycaemic episodes             
ADA classification 44 57·1 3229·2 49 63·6 2673·7 52 68·4 3777·1 46 59·7 2919·6 
Severe 2 2·6 8·6 1 1·3 3·0 0 0·0 0·0 1 1·3 3·0 
Severe or blood glucose-confirmed symptomatic b 27 35·1 618·9 27 35·1 392·7 37 48·7 697·1 23 29·9 714·3 
Hyperglycaemic episodes c 28 36·4 876·8 20 26·0 223·6 31 40·8 1005·7 17 22·1 333·3 
Diabetic ketoacidosis 0 0·0 0·0 0 0·0 0·0 1 1·3 0·9 1 1·3 0·9 
a Events reported at an overall rate of ≥10 events per 100 participant-years of observation. 
b Severe or blood glucose-confirmed symptomatic’ hypoglycaemic episodes are either severe according to the ADA classification27 or an episode 
confirmed by a plasma blood glucose value <3.1 mmol/L (56 mg/dL) and with symptoms consistent with hypoglycaemia. This hypoglycaemia 
classification was the endpoint used for the pre-specified statistical analysis of hypoglycaemia. 
c Hyperglycaemic episodes are defined as and confirmed by plasma glucose values >16.7 mmol/l (300 mg/dl). ADA, American Diabetes Association; 
IL, interleukin; N, number of participants with at least one event/episode; %, proportion of participants with at least one event/episode; R, 
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Research in context 
Evidence before this study  
Prevention of type 1 diabetes would require early modulation of the pathway that leads to autoimmune destruction of 
beta cells in the pancreatic islets of Langerhans. Recent insights into the mechanisms of disease in type 1 diabetes have 
led to clinical trials of several novel therapies. New strategies designed to regulate the immune system include the use 
of antigen-based immunotherapies and immunomodulatory or immunosuppressive agents. However, side-effects 
associated with systemic immune suppression and/or the partial nature of the observed efficacy have contributed to the 
lack of regulatory approval of these therapies so far. A single agent or approach seems unlikely to halt disease 
progression in all people with type 1 diabetes.  
 
Added value of this study  
We hypothesized that a compound with low-grade and transient immune-modifying effects combined with a therapy to 
improve beta-cell function would synergise to offer efficacy-related benefits on beta-cell survival but with lower risk of 
the complications generally associated with immune suppression. In this randomised, double-blind trial with 308 adult 
patients with recent-onset diabetes and residual C-peptide secretion, combination treatment of anti-IL-21 and liraglutide 
for 54 weeks was well-tolerated and resulted in sustained endogenous insulin secretion and improved glucose 
metabolism compared with placebo. To date, the present trial is the largest of its kind in adults and in contrast to most 
other investigations, it included an off-drug follow-up period. 
 
Implications of all the available evidence  
Combination therapy with agents such as anti-IL-21 and liraglutide could constitute a potential novel disease-modifying 
therapy by preserving endogenous beta-cell function. The beta-cell preservation observed in the present trial appears at 
least on par with what has been seen in other similar disease-modifying trials in type 1 diabetes. While reported adverse 
events were few and benign indicating a favourable safety profile, the long-term safety of the therapy remains to be 
evaluated. The results obtained from this study imply that beta-cell function could be preserved longer if treatment had 
been continued, ensuring added benefit for patients. Moreover, prevention of type 1 diabetes might become a reality if 
this regimen were to be given to high-risk patients with Stage-1 or Stage-2 type 1 diabetes. 
